-+ 0.00%
-+ 0.00%
-+ 0.00%
IN8BIO Publishes Presentation on Glioblastoma Cell Therapy Research
Share
Listen to the news
IN8BIO Publishes Presentation on Glioblastoma Cell Therapy Research
  • IN8BIO published its SNO 2026 presentation on glioblastoma trials involving 17 patients.
  • Repeat-dose patients had median overall survival of 20.9 months; median progression-free survival reached 13 months.
  • Two-year survival was 50% among the 14 repeat-dose patients.
  • No treatment-related serious adverse events or treatment-related deaths were reported.
  • Enrollment was suspended in 2024 because of funding constraints; data collection on enrolled patients continues.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending